Risk factors which predict biopsy upgrading over time in active surveillance for prostate cancer. Impact of 68Ga-PSMA-11 PET on the management of biochemically recurrent prostate cancer in a ...

Ultragenyx Pharmaceutical has announced plans to discontinue the development of the investigational treatment UX007 for patients with glucose transporter type-1 deficiency syndrome (Glut1 DS) ...

The cover for issue 57 of Oncotarget features figure 2, 'Overall survival analysis of GLUT1, PD-L1, and histologic architecture,' by Chamseddin, et al. The cover for issue 57 of Oncotarget features ...

Glucose is the primary source of energy and substrate for cells, and its uptake through the cell plasma membrane is largely dependent on the glucose transport (GLUT) family. GLUT1, one of the GLUT ...

None — 12-year-old Remi Savioz was diagnosed with a rare neuro-metabolic brain disease called Glucose Transporter 1, which affects the amount of glucose that reaches the brain. She is one of only 200 ...

A tiny change in the very flexible segments of some proteins is enough to trigger rare disorders such as Glut1 deficiency syndrome. A study found that other genetic disorders might be traced back to ...

Ultragenyx is abandoning its glucose transporter type-1 deficiency syndrome (Glut1 DS) program after its drug UX007 missed its endpoints in a phase 3 trial of the rare genetic disorder. This doesn’t ...